image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 159.99
-2.97 %
$ 23.3 B
Market Cap
14.54
P/E
1. INTRINSIC VALUE

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.[ Read More ]

The intrinsic value of one BIIB stock under the base case scenario is HIDDEN Compared to the current market price of 160 USD, Biogen Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BIIB

image
FINANCIALS
9.84 B REVENUE
-3.32%
1.3 B OPERATING INCOME
-44.11%
1.16 B NET INCOME
-60.78%
1.55 B OPERATING CASH FLOW
11.77%
-4.1 B INVESTING CASH FLOW
-260.12%
149 M FINANCING CASH FLOW
108.48%
2.47 B REVENUE
4.79%
451 M OPERATING INCOME
-30.87%
388 M NET INCOME
-33.43%
936 M OPERATING CASH FLOW
49.50%
-1.18 B INVESTING CASH FLOW
-253.18%
-6.6 M FINANCING CASH FLOW
97.31%
Balance Sheet Decomposition Biogen Inc.
image
Current Assets 6.86 B
Cash & Short-Term Investments 1.05 B
Receivables 2.1 B
Other Current Assets 3.71 B
Non-Current Assets 20 B
Long-Term Investments 461 M
PP&E 3.73 B
Other Non-Current Assets 15.8 B
Current Liabilities 3.43 B
Accounts Payable 403 M
Short-Term Debt 240 M
Other Current Liabilities 2.79 B
Non-Current Liabilities 8.61 B
Long-Term Debt 7.19 B
Other Non-Current Liabilities 1.42 B
EFFICIENCY
Earnings Waterfall Biogen Inc.
image
Revenue 9.84 B
Cost Of Revenue 2.53 B
Gross Profit 7.3 B
Operating Expenses 7.3 B
Operating Income 1.3 B
Other Expenses 135 M
Net Income 1.16 B
RATIOS
74.24% GROSS MARGIN
74.24%
13.18% OPERATING MARGIN
13.18%
11.81% NET MARGIN
11.81%
7.85% ROE
7.85%
4.33% ROA
4.33%
5.34% ROIC
5.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Biogen Inc.
image
Net Income 1.16 B
Depreciation & Amortization 495 M
Capital Expenditures -311 M
Stock-Based Compensation 264 M
Change in Working Capital -649 M
Others -67.5 M
Free Cash Flow 1.24 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Biogen Inc.
image
Wall Street analysts predict an average 1-year price target for BIIB of $277 , with forecasts ranging from a low of $202 to a high of $342 .
BIIB Lowest Price Target Wall Street Target
202 USD 26.26%
BIIB Average Price Target Wall Street Target
277 USD 73.01%
BIIB Highest Price Target Wall Street Target
342 USD 113.76%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Biogen Inc.
image
Sold
0-3 MONTHS
88 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
102 K USD 1
9-12 MONTHS
284 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
101 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 03, 2024
Sell 88 K USD
Singhal Priya
Head of Development
- 431
204.22 USD
7 months ago
Apr 02, 2024
Sell 19.8 K USD
Singhal Priya
Head of Development
- 93
213.09 USD
8 months ago
Feb 22, 2024
Sell 58 K USD
Singhal Priya
Head of Development
- 262
221.23 USD
9 months ago
Feb 16, 2024
Sell 23.9 K USD
Singhal Priya
Head of Development
- 108
221.49 USD
9 months ago
Feb 15, 2024
Bought 101 K USD
Rowinsky Eric K
Director
+ 455
222.54 USD
9 months ago
Feb 12, 2024
Sell 100 K USD
Singhal Priya
Head of Development
- 419
239.45 USD
9 months ago
Feb 02, 2024
Sell 156 K USD
Singhal Priya
Head of Development
- 634
245.93 USD
11 months ago
Dec 11, 2023
Sell 27.3 K USD
Singhal Priya
Head of Development
- 110
248 USD
1 year ago
Sep 05, 2023
Sell 116 K USD
Singhal Priya
Head of Development
- 431
269.43 USD
1 year ago
Jul 03, 2023
Sell 22.9 K USD
Singhal Priya
Head of Development
- 81
282.87 USD
1 year ago
Apr 28, 2023
Sell 804 K USD
Gregory Ginger
EVP, Human Resources
- 2681
300 USD
1 year ago
Apr 04, 2023
Sell 25.2 K USD
Singhal Priya
Head of Development
- 91
277.11 USD
1 year ago
Mar 28, 2023
Sell 153 K USD
Singhal Priya
Head of Development
- 568
270.06 USD
2 years ago
Nov 14, 2022
Sell 1.68 M USD
Gregory Ginger
EVP, Human Resources
- 5610
300.11 USD
2 years ago
Oct 27, 2022
Sell 1.55 M USD
ALEXANDER SUSAN H
EVP Chief Legal Off & Corp Sec
- 5532
280.7 USD
3 years ago
Jun 07, 2021
Sell 3.38 M USD
Sandrock Alfred
Head of Research & Development
- 7672
440 USD
3 years ago
Jun 07, 2021
Sell 1.36 M USD
Guindo Chirfi
Head of Glob Prod Strat & Com
- 3087
440 USD
3 years ago
Jun 04, 2021
Sell 98.7 K USD
Posner Brian S
Director
- 360
274.17 USD
3 years ago
Feb 09, 2021
Bought 240 K USD
Mantas Jesus B
Director
+ 898
267 USD
3 years ago
Nov 30, 2020
Bought 748 K USD
Vounatsos Michel
Chief Executive Officer
+ 3100
241.3054 USD
4 years ago
Nov 04, 2020
Sell 525 K USD
Sandrock Alfred
EVP, Research & Development
- 1500
350 USD
7. News
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease. zacks.com - 2 days ago
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug. marketwatch.com - 2 days ago
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or heterozygotes with confirmed amyloid pathology.1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is expected to make a final decision on the marketing authorization application (MAA) of lecanemab based on the CHMP recommendation within 67 days of receipt of CHMP opinion.2 globenewswire.com - 3 days ago
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment. reuters.com - 3 days ago
Biogen initiated with a Neutral at Citi Citi analyst Geoff Meacham initiated coverage of Biogen with a Neutral rating and $190 price target. The company's strategy to offset core franchise erosion has been to develop assets with significant unmet need in very difficult indications, the analyst tells investors in a research note. The firm says Biogen's pipeline still looks to have higher clinical risk overall versus the company's big biotech peers, "but this also conveys significant option value." https://thefly.com - 3 days ago
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com - 5 days ago
BIIB vs. MYGN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors a better bang for their buck right now? zacks.com - 1 week ago
Are Investors Undervaluing Biogen (BIIB) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 week ago
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Biogen (BIIB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 1 week ago
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter Biogen reported its Q3 earnings yesterday, October 30. Revenue of $2.5bn was reported and non-GAAP EPS of $4.08. Growth was generally flat or declining for many key assets, with the performance of AD drug Leqembi especially underwhelming. seekingalpha.com - 2 weeks ago
Biogen Analysts Slash Their Forecasts After Q3 Results Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. benzinga.com - 2 weeks ago
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference -New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD- globenewswire.com - 2 weeks ago
8. Profile Summary

Biogen Inc. BIIB

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 23.3 B
Dividend Yield 0.00%
Description Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Contact 225 Binney Street, Cambridge, MA, 02142 https://www.biogen.com
IPO Date Sept. 17, 1991
Employees 7570
Officers Dr. Stephen Amato Head of Investor Relations Mr. Christopher A. Viehbacher President, Chief Executive Officer & Director Mr. Michael R. McDonnell CPA Executive Vice President & Chief Financial Officer Ms. Nicole Murphy Head of Pharmaceutical Operations & Technology Ms. Susan H. Alexander Esq. Executive Vice President & Chief Legal Officer Mr. Rachid Izzar Head of Global Product Strategy & Commercialization Ms. Robin C. Kramer Senior Vice President & Chief Accounting Officer Ms. Natacha Gassenbach Chief Communication Officer & Head of Corporate Affairs Mr. Adam Keeney Ph.D. Executive Vice President & Head of Corporate Development Dr. Ginger Gregory Ph.D. Executive Vice President & Chief Human Resources Officer